This was a study in which we were one of the participating institutions and it’s an international collaboration looking at women who carry mutations in the BRCA genes and who were diagnosed with breast cancer at age 40 or younger. In this analysis, we sought to look at the association between age at diagnosis and breast cancer outcomes. Previous studies have suggested that women who are very young at the time of their breast cancer diagnosis have a worse prognosis...
This was a study in which we were one of the participating institutions and it’s an international collaboration looking at women who carry mutations in the BRCA genes and who were diagnosed with breast cancer at age 40 or younger. In this analysis, we sought to look at the association between age at diagnosis and breast cancer outcomes. Previous studies have suggested that women who are very young at the time of their breast cancer diagnosis have a worse prognosis. So in this cohort, we looked at age categories of 30 and under versus 31 to 35 and 36 to 40. And we found that there was actually no difference in either disease-free survival or overall survival based on age category. We did see a little bit higher prevalence of BRCA1 versus BRCA2 mutations in the very young cohort. And correlating with that, more high-grade tumors, more triple-negative tumors, and more use of chemotherapy. But with the appropriate treatment, we saw very similar outcomes regardless of age category.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
